Topics
Mental health
The aftermath of loss
Why had we all chosen specialties that walk hand in hand with the spectre of death — at once fighting and accepting its inevitability?
Catriona McNeil
Integrated (one-stop shop) youth health care: best available evidence and future directions
Although mental health problems represent the largest burden of disease in young people, access to mental health care has been poor for this group
Sarah E Hetrick · Alan P Bailey · Kirsten E Smith · Ashok Malla · Steve Mathias · Swaran P Singh · Aileen O'Reilly · Swapna K Verma · Laelia Benoit · Theresa M Fleming · Marie Rose Moro · Debra J Rickwood · Joseph Duffy · Trissel Eriksen · Robert Illback · Caroline A Fisher · Patrick D McGorry
Targeting mental health care attributes by diagnosis and clinical stage: the views of youth mental health clinicians
Promoting routine, consistent collection of clinical stage data may enhance appropriate targeting of mental health care delivery
Matthew P Hamilton · Sarah E Hetrick · Cathrine Mihalopoulos · David Baker · Vivienne Browne · Andrew M Chanen · Kerryn Pennell · Rosemary Purcell · Heather Stavely · Patrick D McGorry
Identifying attributes of care that may improve cost-effectiveness in the youth mental health service system
More economic evaluations are required in youth mental health
Matthew P Hamilton · Sarah E Hetrick · Cathrine Mihalopoulos · David Baker · Vivienne Browne · Andrew M Chanen · Kerryn Pennell · Rosemary Purcell · Heather Stavely · Patrick D McGorry
Youth mental health: building beyond the brand
Youth mental health is a hot topic. How much progress have we made, and what’s next?
Patrick D McGorry
Diagnosing, monitoring and managing behavioural variant frontotemporal dementia
Detailed medical history, carer information, targeted neuropsychological testing and brain neuroimaging help to differentiate bvFTD from other dementia syndromes
Olivier Piguet · Fiona Kumfor · John Hodges
Influence of birth month on the probability of Western Australian children being treated for ADHD
To the Editor:Whitely and colleagues1 reported that children born in June were more likely to receive treatment for attention deficit/hyperactivity disorder (ADHD) than children born in July. It is unfortunate that they did not measure the year of school intake, and rather made the assumption that all children entered school at the recommended age. The authors concluded that “there are significant concerns about the validity of ADHD as a diagnosis,” which is a large leap not substantiated by the data presented. We are conducting Australia’s first community-based longitudinal study of children with (n = 179) and without ADHD (n = 212), the Children’s Attention Project.2,3 Our design is ideal for examining this research question as children were all recruited across one year of school, enabling us to accurately categorise children as early or late starters. We rigorously assessed for ADHD (ie, via parent and teacher surveys and diagnostic interviews) and also recorded the use of ADHD medications. To investigate the same question within our cohort, we defined early starters as those children with birth months in February, March or April (age at entry, 4 years 9 months to 4 years 11 months; n = 46) and late starters as those children born in May, June or July (age at entry, 5 years 6 months to 5 years 8 months; n = 123). We found no relationship between being an early or late starter and meeting the criteria for ADHD at either age 7 years or age 10 years. Our sample size for these analyses was small because most children with ADHD were born outside the months encapsulating early and late start date definitions (n = 112; 63% of our ADHD sample). Only nine children were prescribed medication across the early and late starter definitions — one early starter and eight late starters. In conclusion, our data show that when school commencement year is considered, there is little evidence to support early versus late school starter status as a predictor of ADHD and treatment in Victoria. The overall rate of ADHD medication prescribing for children aged 6–15 years reported by Whitely and colleagues was 1.9%.1 ADHD has a prevalence of about 5%,4 thus, these data provide further reassurance that the rates of prescribing of ADHD medications in Australia remain moderate.
Emma Sciberras · Alisha Gulenc · Daryl Efron
Influence of birth month on the probability of Western Australian children being treated for ADHD
In reply
Martin Whitely · John Phillimore · Leanne Lester · Suzanne Robinson
Cardiovascular disease in patients with schizophrenia
To the Editor:I thank Kritharides and colleagues1 for their review Cardiovascular disease in patients with schizophrenia. I agree with them and support their work, which seeks to improve the physical health of patients living in the community with a chronic mental illness such as schizophrenia, through an innovative, coordinated and multidisciplinary model of care. Clozapine side effects, including risks of myocarditis and cardiomyopathy, hypercholesterolaemia and weight gain, reduce years of life and require medical attention. But the management is not always straightforward. One challenge is patient compliance with often demanding allied health therapies. How do we keep our patients motivated to continue with prescribed regular exercise most days of the week? How do we encourage compliance with a weight-reducing, low salt, low glycaemic index diet? Multidisciplinary primary care and specialist teams may consider a rehabilitation approach to complement the model of care. Two essential elements are goal setting and measurement of function.2 Some patients will be motivated by their personal goals (eg, getting back to weighing 80 kg or playing a game of table tennis) and other patients will appreciate their gain in terms of function (eg, walking up the stairs without a rest or shopping for groceries independently) more so than in terms of presented data (eg, cholesterol levels or absolute cardiovascular risk reduction). For motivating patients with schizophrenia and significant cardiovascular risk, a rehabilitation approach may be worth a try.
David Skalicky
Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia
Contemporary research suggests potential benefits of psychedelic drugs in treatment-resistant depression and terminally ill patients
Nigel Strauss
Why medically unexplained symptoms and health anxiety don’t need to make your heart sink
Cognitive behaviour therapy is an effective strategy for overcoming the challenges of health anxiety
Jill M Newby · Gavin Andrews
Psychiatry training: survive and thrive
Psychiatry in practice: education, experience and expertise
Cherrie A Galletly
The disparity between changes in the prevalence of mental illness and disability support rates in Australia
Clarifying the type of support needed by people with a psychiatric disability must be a priority
Harvey A Whiteford
Broken promises and missing steps in mental health reform
We are still seriously failing to resource and integrate mental health into the mainstream of the health care system
Patrick D McGorry · Matthew P Hamilton
Is the prevalence of mental illness increasing in Australia? Evidence from national health surveys and administrative data, 2001–2014
The increasing costs and disability associated with mental ill-health are not correlated with any increase in its prevalence
Samuel B Harvey · Mark Deady · Min-Jung Wang · Arnstein Mykletun · Peter Butterworth · Helen Christensen · Philip B Mitchell
The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders
This update to the 2005 RANZCP guidelines has a greater emphasis on psychosocial treatments, physical health comorbidities and vocational rehabilitation
David J Castle · Cherrie A Galletly · Frances Dark · Verity Humberstone · Vera A Morgan · Eóin Killackey · Jayashri Kulkarni · Patrick McGorry · Olav Nielssen · Nga T Tran · Assen Jablensky
Suicide by health professionals: a retrospective mortality study in Australia, 2001–2012
To the Editor:We commend Milner and colleagues on their most important and timely study, which investigated the age-standardised rates and methods of suicide by health professionals compared with other occupational groups.1 They established that suicide rates for female health professionals, including medical professionals, were higher than for women in other occupations. While suicide rates were higher for male nurses and midwives, those for male medical practitioners were not significantly higher compared with other occupational groups.1 Milner and colleagues considered sex-related stressors in their discussion, in an attempt to understand the gender differences in suicide rates among medical professionals. The authors considered that women working in male-dominated areas face “considerable gender role stress” and may feel pressure to undertake traditional household roles and family responsibilities.1 It is highly conceivable that the abovementioned sex-related stressors may contribute to the sex differential in suicide rates. However, sexual harassment is an important sex-related stressor2 that was not included in their discussion or in Goldney’s accompanying editorial on this topic.3 There is overwhelming evidence to suggest that sexual harassment disproportionately affects women and is an entrenched problem in the medical profession.4,5 Indeed, sexual harassment has been demonstrated to be associated with suicide attempts among female doctors.5 Goldney argues that “ensuring good workplace relationships and equal opportunity, eliminating bullying [and] reducing access to means of suicide” are important pragmatic approaches to overcoming the problem of suicide among health care professionals.3 We propose that redressing sexual inequalities in medicine and eliminating sexual harassment might represent some additional approaches.
Nikki R Adler · Kimberley A Adler
Suicide by health professionals: a retrospective mortality study in Australia, 2001–2012
In reply:In their comment on our article,1 Adler and Adler are correct in noting that sexual harassment is a significant issue facing female doctors, as it is for women in many occupations.2 Those who experience sexual harassment are also more likely to experience bullying and other forms of workplace incivility.3 Workplace bullying has also been found to be related to higher risk of suicidality.4 In view of this, we agree that these would be worthwhile targets for prevention initiatives. But the question remains as to whether sexual harassment and the problems regarding gender role stress discussed in our article1 all stem from the same set of causes. A meta-analysis3 noted two systematic sources of sexual harassment: (i) organisational context, including a climate that permits sexual harassment, and policies that do not support the reporting of and action against perpetrators; and (ii) the context of gender in the workplace — for example, the extent to which traditional gender roles are able to be maintained, such as through gender differences in the organisation of work, and the overall proportion of women employed in the job. In our article, we specifically highlighted the maintenance of gender-normative behaviour in medicine as potential stressors for suicide. While we agree that sexual harassment is a significant issue that needs to be addressed, we suggest that this be incorporated into a wider and overall strategy to overcome gender inequality in medicine. This strategy should target the negative personal and organisational (eg, organisation commitment, work withdrawal, job satisfaction) outcomes of harassment,3 and include measures to allow both male and female doctors to care for their families. In addition, to align with best practice in workplace suicide prevention,5 we would also support a stigma reduction campaign, access to treatment for health practitioners who experience poor mental health and suicidal ideation, and support for colleagues and families following bereavement from suicide within the medical profession.
Allison J Milner · Matthew J Spittal · Marie M Bismark
Suicide by health professionals: a retrospective mortality study in Australia, 2001–2012
In reply:I thank Adler and Adler for their comment on my editorial on suicide by health care professionals.1 Their proposal of “redressing sexual inequalities in medicine and eliminating sexual harassment” appears to be encompassed in my statement about “ensuring good workplace relationships and equal opportunity [and] eliminating bullying”,1 which they quote in their letter. Regrettably, sexual harassment is common and not unique to medicine, with an estimated prevalence in the workplace of 35–50%.2 Although Adler and Adler refer to the work of Frank and colleagues3 in demonstrating an association between sexual harassment and suicide attempts in female doctors, they do not mention the caveats that the study authors noted. These include that it was “a relationship we cannot determine”; that earlier studies were “based on small numbers and the subject of considerable controversy”; and that “these problems are not unique to women physicians”. Bearing in mind the low base rate discussed in my article, ensuring that equal opportunity, good workplace relations and anti-bullying approaches are standard for health practitioners, and that health practitioners can access general and mental health care, are more realistic and achievable goals that are more likely to return dividends.
Robert Goldney
Coronary occlusion, denial and dissociation
A doctor puts emotions aside in an emergency, but dissociation does not help when the illness is in the family
Ruth A Stewart
Reducing the burden of neurological disease and mental illness
The key to finding solutions for brain disorders is cooperation and collaboration from the laboratory to the clinic
Kay L Double · Linda J Richards
Clozapine-induced maculopathy
A 57-year-old man was treated for schizophrenia with clozapine 900 mg daily over 22 years. His history included epilepsy, hypertension and hypercholesterolaemia, which was treated with clonazepam, clonidine and atorvastatin. Examination showed acuity 6/5 bilaterally, corneal and macular pigmentation (Figure, A, arrow, compared with B, which is normal macula), with subfoveal atrophy and disruption of the photoreceptor-retinal pigment epithelium junction on optical coherence tomography scan ([OCT]; Figure, C compared with D, which is a normal OCT, arrows), and left eye macular dysfunction on multifocal electroretinography ([ERG]; Figure, E compared with F, which is a normal ERG). These changes were similar to previously described clozapine-associated retinopathy.1 Clonazepam is associated with depigmentary retinopathy and normal ERG responses.2 Clonidine and atorvastatin have no documented retinopathy. The patient’s hyperpigmentation may be due to clozapine absorption via the choroid, binding to retinal pigment epithelium and interrupting photoreceptor phagocytosis.3 High dose clozapine warrants ophthalmic follow-up. Figure
Jessica Y Tong · Amy Pai · Peter Heydon · Stephanie H Young
Post-traumatic stress disorder is a systemic illness, not a mental disorder: is Cartesian dualism dead?
Mind and body are intimately linked, in health and in disease
Alexander C McFarlane
Physical comorbidities of post-traumatic stress disorder in Australian Vietnam War veterans
A comprehensive approach to the health care of veterans with PTSD is needed
Sarah C McLeay · Wendy M Harvey · Madeline NM Romaniuk · Darrell HG Crawford · David M Colquhoun · Ross McD Young · Miriam Dwyer · John M Gibson · Robyn A O'Sullivan · Graham Cooksley · Christopher R Strakosch · Rachel M Thomson · Joanne Voisey · Bruce R Lawford